OMER
Price
$16.88
Change
+$0.62 (+3.81%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.18B
21 days until earnings call
Intraday BUY SELL Signals
VCYT
Price
$46.05
Change
-$0.17 (-0.37%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
3.72B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OMER vs VCYT

OMER vs VCYT Comparison Chart in %
View a ticker or compare two or three
VS
OMER vs. VCYT commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OMER is a StrongBuy and VCYT is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for OMER with price predictions
Oct 21, 2026

OMER's RSI Indicator ascends from oversold territory

The RSI Indicator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 67 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

OMER moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for OMER entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.922) is normal, around the industry mean (2.988). P/E Ratio (8.469) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VCYT with price predictions
Oct 21, 2026

VCYT in upward trend: 10-day moving average crossed above 50-day moving average on October 02, 2026

The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 66 cases where VCYT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 79 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 38 of 52 cases over the following month. The odds of a continued upward trend are 73%.

VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

VCYT broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.676) is normal, around the industry mean (64.450). P/E Ratio (32.097) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

FUNDAMENTALS RATINGS
OMER vs VCYT: Fundamental Ratings
OMER
VCYT
OUTLOOK RATING
1..100
6834
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
1175
PRICE GROWTH RATING
1..100
3643
P/E GROWTH RATING
1..100
7495
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OMER's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for VCYT (70). This means that OMER’s stock grew somewhat faster than VCYT’s over the last 12 months.

OMER's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as VCYT (100). This means that OMER’s stock grew similarly to VCYT’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is somewhat better than the same rating for VCYT (75). This means that OMER’s stock grew somewhat faster than VCYT’s over the last 12 months.

OMER's Price Growth Rating (36) in the Biotechnology industry is in the same range as VCYT (43). This means that OMER’s stock grew similarly to VCYT’s over the last 12 months.

OMER's P/E Growth Rating (74) in the Biotechnology industry is in the same range as VCYT (95). This means that OMER’s stock grew similarly to VCYT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OMERVCYT
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 4 days ago
82%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (OMER: $16.26 vs. VCYT: $46.22)
Brand notoriety: OMER and VCYT are both not notable
OMER represents the Biotechnology, while VCYT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: OMER: 46% vs. VCYT: 60%
Market capitalization -- OMER: $1.22B vs. VCYT: $3.7B
OMER [@Biotechnology] is valued at $1.22B. VCYT’s [@Medical Specialties] market capitalization is $3.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Biotechnology] industry is $2.18B. The average market capitalization across the [@Medical Specialties] industry is $20.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OMER’s FA Score shows that 2 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).

  • OMER’s FA Score: 2 green, 3 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, OMER is a better buy in the long-term than VCYT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OMER’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 7 bullish TA indicator(s).

  • OMER’s TA Score: 4 bullish, 6 bearish.
  • VCYT’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, VCYT is a better buy in the short-term than OMER.

Price Growth

OMER (@Biotechnology) experienced а -11.77% price change this week, while VCYT (@Medical Specialties) price change was +6.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.

Reported Earning Dates

OMER is expected to report earnings on Nov 12, 2026.

VCYT is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (-3.15% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
OMER
Daily Signal:
Gain/Loss:
VCYT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with GNPX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
-1.75%
GNPX - OMER
51%
Loosely correlated
-3.76%
VCYT - OMER
40%
Loosely correlated
+3.19%
INM - OMER
36%
Loosely correlated
+2.99%
TOVX - OMER
35%
Loosely correlated
-5.48%
ABSI - OMER
34%
Loosely correlated
+10.69%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ETH23.800.57
+2.45%
Grayscale Ethereum Staking Mini ETF (ETH)
PAYH25.000.19
+0.78%
TrueShares S&P Autocallable High Income ETF (PAYH)
QVMT64.290.13
+0.20%
Invesco S&P 500 Concentrated QVM ETF (QVMT)
CTEX30.46N/A
N/A
ProShares S&P Kensho Cleantech ETF (CTEX)
FLIA20.09-0.02
-0.12%
Franklin International Aggregate Bond ETF (FLIA)